dihydroergotamine mesylate DPI (ASY202) / Aspeya - LARVOL DELTA

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: Aspeya, Inc. | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • CNS Disorders • Migraine

Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Aspeya, Inc. | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Aspeya, Inc.

New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases